| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash provided by investing activities | 40,851 | 25,139 |
| Repayment of loan principal | 3,913 | 2,608 |
| Proceeds from issuance of common stock under employee stock incentive plans | 35 | 35 |
| Net cash (used in) provided by financing activities | -3,878 | -2,573 |
| Effect of exchange rate changes on cash and cash equivalents | 28 | 37 |
| Net decrease in cash and cash equivalents | -2,814 | -7,382 |
| Cash and cash equivalents at beginning of period | 41,749 | - |
| Cash and cash equivalents at end of period | 38,935 | - |
Kezar Life Sciences, Inc. (KZR)
Kezar Life Sciences, Inc. (KZR)